SCHEMBL2084881

SCHEMBL2084881

O=C(O)CCNC1CCc2cc(-c3cc4cc(Cc5ccccc5)ccc4o3)ccc21

nearest known ligand 0.49

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 6/20 0.49
FFAR1 O14842 9/20 0.47
S1PR3 Q99500 2/20 0.47
KCNH2 Q12809 1/20 0.41
CYP26A1 O43174 1/20 0.40
CYP26B1 Q9NR63 1/20 0.40
MAOB P27338 3/20 0.37
MAOA P21397 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1601244 0.83 S1PR1 (0.52) S1PR1FFAR1S1PR3KCNH2CYP26A1
SCHEMBL1602329 0.73 S1PR1 (0.53) S1PR1FFAR1S1PR3KCNH2CYP26A1
SCHEMBL12269270 0.72 S1PR1 (0.48) S1PR1FFAR1S1PR3KCNH2CYP26A1
SCHEMBL12269128 0.70 HTR2C (0.55) MAOBMAOA
SCHEMBL12269279 0.69 S1PR1 (0.68) S1PR1FFAR1S1PR3KCNH2MAOB
SCHEMBL2942134 0.68 S1PR1 (0.56) S1PR1FFAR1S1PR3
Trifluoroacetic Acid SCHEMBL1602523 0.68 S1PR1 (0.43) S1PR1FFAR1S1PR3KCNH2CYP26A1
SCHEMBL13233832 0.68 S1PR1 (0.44) S1PR1FFAR1S1PR3CYP26A1CYP26B1
SCHEMBL1601933 0.68 S1PR1 (0.48) S1PR1FFAR1S1PR3KCNH2CYP26A1
SCHEMBL1602267 0.67 S1PR1 (0.81) S1PR1FFAR1S1PR3KCNH2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110059945-A1 S1P Receptor Modulating Compounds and Use Thereof EPIX PHARMACEUTICALS, INC. (US) 2011-03-10 US claimed
JP-2010522162-A 2010-07-01 JP claimed
EP-2121648-A2 S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF EPIX Pharmaceuticals, Inc. (US) 2009-11-25 EP claimed
EP-1965807-A2 S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF Epix Delaware, Inc. (US) 2008-09-10 EP claimed
US-20080064677-A9 S1P receptor modulating compounds and use thereof PREDIX PHARMACEUTICAL HOLDINGS 2008-03-13 US claimed
US-20080027036-A1 S1P receptor modulating compounds and use thereof EPIX DELAWARE, INC. (US) 2008-01-31 US claimed
WO-2007109334-A2 SIP RECEPTOR MODULATING COMPOUNDS AND USE THEREOF EPIX DELAWARE, INC. (US) 2007-09-27 WO claimed
US-20070173487-A1 S1P receptor modulating compounds and use thereof PREDIX PHARMACEUTICAL HOLDINGS 2007-07-26 US claimed
WO-2007061458-A2 S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF EPIX DELAWARE, INC. (US) 2007-05-31 WO claimed
EP-2364976-A1 S1P receptor modulating compounds and use thereof EPIX Pharmaceuticals, Inc. (US) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027036-A1 S1P receptor modulating compounds and use thereof S1PR1, S1PR5, S1PR2 S1PR1 1/4885FFAR1 31/4885S1PR3 5/4885
US-20080064677-A9 S1P receptor modulating compounds and use thereof S1PR1, S1PR5, S1PR2 S1PR1 1/4885FFAR1 31/4885S1PR3 5/4885
US-20110059945-A1 S1P Receptor Modulating Compounds and Use Thereof S1PR1, S1PR5, S1PR2 S1PR1 1/4885FFAR1 31/4885S1PR3 5/4885
US-20070173487-A1 S1P receptor modulating compounds and use thereof S1PR1, S1PR5, S1PR2 S1PR1 1/4885FFAR1 31/4885S1PR3 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.